A recent study by Wang et al. [53] found that CTX significantly inhibited breast cancer cell proliferation, migration, and invasion through binding to estrogen receptor alpha (ERα) to inhibit the expression of ERα, which inhibits the ERα/vasodilator-stimulated phosphoprotein (VASP) signaling pathway. This evidence concerns the gene VASP and breast carcinoma.